Clinical trial NCT00293332 (phase 2, status: terminated)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, docetaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    terminated due to low subject accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed non-small cell lung cancer

               -  No squamous cell carcinoma

               -  No histology in close proximity to a major vessel

          -  Resectable stage IB-IIIA disease

          -  No CNS or brain metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-1

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 8.0 g/dL

          -  Bilirubin normal

          -  Creatinine ≤ 1.5 mg/dL

          -  Urine protein:creatinine < 1.0

          -  Alkaline phosphatase (AP), AST, and ALT must meet 1 of the following criteria:

               -  AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)

               -  AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN

               -  AP ≤ 5 times ULN AND AST and ALT normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 3 months
             after completion of study treatment

          -  Adequate pulmonary and cardiovascular function to tolerate surgical resection

          -  No cavitation or history of hemoptysis (i.e., bright red blood ≥ ½ teaspoon)

          -  No existing peripheral neuropathy ≥ grade 1

          -  No known history of severe hypersensitivity reaction to drugs formulated with
             polysorbate 80

          -  No history of serious systemic disease, including any of the following:

               -  Myocardial infarction within the past 6 months

               -  Uncontrolled hypertension (i.e., blood pressure > 150/110 mm Hg on medication)

               -  Unstable angina

               -  New York Heart Association class II-IV congestive heart failure

               -  Unstable symptomatic arrhythmia requiring medication

                    -  Patients with chronic atrial arrhythmia (i.e., atrial fibrillation or
                       paroxysmal supraventricular tachycardia) are eligible

               -  Clinically significant peripheral vascular disease (i.e., grade II or higher)

          -  No history of significant neurological or psychiatric condition

          -  No known active infection within the past 14 days

          -  No serious, nonhealing wound, ulcer, or bone fracture

          -  No evidence of bleeding diathesis or coagulopathy

          -  No stroke within the past 6 months

          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within
             the past 28 days

          -  No other serious illness or medical condition

          -  No active infection

          -  No other currently active malignancy except nonmelanoma skin cancer

               -  Malignancies for which therapy has been completed and are considered to have ≤
                  30% chance of risk of relapse are not considered active

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy or VEGF inhibitor

          -  No prior (i.e., within the past 4 weeks), concurrent, or anticipated participation in
             another experimental drug study except a Genentech-sponsored bevacizumab cancer study

          -  No major surgical procedure, open biopsy, or significant traumatic injury within the
             past 28 days

          -  No anticipation for major surgical procedure during study treatment

          -  No fine-needle aspiration or core biopsy within 7 days prior to study entry

          -  No concurrent full-dose anticoagulation

          -  No other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational
             therapy for this cancer